Shandong Xinhua Pharmaceutical Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2023: 0.012x

Shandong Xinhua Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.11 Million ≈ $8.21 Million USD) by net assets (CN¥4.70 Billion ≈ $687.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)

Cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Shandong Xinhua Pharmaceutical Co Ltd for real-time trading data and today's change.

Shandong Xinhua Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained

Shandong Xinhua Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Shandong Xinhua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Shandong Xinhua Pharmaceutical Co Ltd (000756) total market value for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Intelbras S.A. - Indústria de Telecomunicação Eletrônica Brasileira
SA:INTB3
0.150x
Jiangyin Hengrun Heavy
SHG:603985
0.009x
First Financial Corporation Indiana
NASDAQ:THFF
0.027x
Helia Group Ltd
AU:HLI
-0.038x
Shenzhen Asiantime International Construction Co Ltd
SHE:002811
0.071x
Hexatronic Group AB
ST:HTRO
0.008x
Sudarshan Chemical Industries Limited
NSE:SUDARSCHEM
-0.036x
Guilin Seamild Foods Co Ltd
SHE:002956
0.081x

Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. Review Shandong Xinhua Pharmaceutical Co Ltd (000756) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.22 Billion
≈ $763.48 Million
CN¥367.61 Million
≈ $53.79 Million
0.070x +26.84%
2023-12-31 CN¥4.78 Billion
≈ $698.84 Million
CN¥265.28 Million
≈ $38.82 Million
0.056x -68.13%
2022-12-31 CN¥4.35 Billion
≈ $636.53 Million
CN¥758.24 Million
≈ $110.95 Million
0.174x +145.62%
2021-12-31 CN¥3.65 Billion
≈ $534.28 Million
CN¥259.12 Million
≈ $37.92 Million
0.071x -42.72%
2020-12-31 CN¥3.39 Billion
≈ $496.25 Million
CN¥420.19 Million
≈ $61.49 Million
0.124x +10.66%
2019-12-31 CN¥3.11 Billion
≈ $455.17 Million
CN¥348.27 Million
≈ $50.96 Million
0.112x -3.33%
2018-12-31 CN¥2.80 Billion
≈ $409.22 Million
CN¥323.91 Million
≈ $47.40 Million
0.116x -23.39%
2017-12-31 CN¥2.58 Billion
≈ $377.46 Million
CN¥389.97 Million
≈ $57.07 Million
0.151x -28.45%
2016-12-31 CN¥2.08 Billion
≈ $304.27 Million
CN¥439.35 Million
≈ $64.29 Million
0.211x +20.25%
2015-12-31 CN¥1.98 Billion
≈ $290.33 Million
CN¥348.64 Million
≈ $51.02 Million
0.176x --

About Shandong Xinhua Pharmaceutical Co Ltd

SHE:000756 China Drug Manufacturers - Specialty & Generic
Market Cap
$918.05 Million
CN¥6.27 Billion CNY
Market Cap Rank
#8973 Global
#2134 in China
Share Price
CN¥12.68
Change (1 day)
+1.60%
52-Week Range
CN¥11.95 - CN¥18.15
All Time High
CN¥44.80
About

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more